Moderna Inc. announced that it will request authorization for the emergency use of its COVID-19 vaccine in the US. Monday, Reuters reported.
The company informed that it will request this Monday the authorization of emergency use also in the European Union. They are based on the complete results of the last stage of the study that showed an effectiveness of 94.1%. It further reported that the COVID-19 vaccine was 100% effective against severe COVID-19 in the phase 3 trial. The efficacy of the COVID-19 vaccine was consistent based on age, race and ethnicity, and gender demographics. .
The US FDA Advisory Committee meeting to be scheduled for December 17. He estimates that the launch trial of the COVID-19 vaccine in adolescents will be before the end of the year.
Moderna clarified that no new serious security problems have been identified since November 16 in the phase 3 trial.
.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
